Prime Medicine, Inc. (PRME)
3.61
+0.48
(+15.34%)
USD |
NASDAQ |
Oct 15, 16:00
3.65
+0.04
(+1.11%)
After-Hours: 20:00
Prime Medicine Research and Development Expense (Quarterly) : 33.40M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 33.40M |
| March 31, 2026 | 34.10M |
| December 31, 2025 | 34.71M |
| September 30, 2025 | 43.99M |
| June 30, 2025 | 41.38M |
| March 31, 2025 | 40.56M |
| December 31, 2024 | 34.10M |
| September 30, 2024 | 40.34M |
| June 30, 2024 | 43.07M |
| March 31, 2024 | 37.77M |
| December 31, 2023 | 41.46M |
| September 30, 2023 | 40.97M |
| Date | Value |
|---|---|
| June 30, 2023 | 34.60M |
| March 31, 2023 | 30.88M |
| December 31, 2022 | 29.06M |
| September 30, 2022 | 25.05M |
| June 30, 2022 | 18.94M |
| March 31, 2022 | 13.68M |
| December 31, 2021 | 52.89M |
| September 30, 2021 | 7.40M |
| June 30, 2021 | 5.695M |
| March 31, 2021 | 4.566M |
| December 31, 2020 | 1.259M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Beam Therapeutics, Inc. | 95.10M |
| Twist Bioscience Corp. | 18.02M |
| Intellia Therapeutics, Inc. | 80.50M |
| Moderna, Inc. | 588.00M |
| Q32 Bio, Inc. | 4.259M |